γ-PNA miR-122 Inhibitors for Endothelial Dysfunction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hypertension and diabetes fail to effectively reduce cardiovascular risks associated with endothelial dysfunction and aberrant miR-122 expression, leading to increased cardiovascular events and complications.
Innovation Solution
Development of γ-PNA oligomers, specifically γ-diethylene glycol-modified oligomers with complementary nucleic acid sequences to miR-122, flanked by lysines, administered with pharmaceutical excipients, to inhibit miR-122 activity and treat associated disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for hypertension and diabetes, then current standard of care is maintained, but cardiovascular risks associated with endothelial dysfunction and aberrant miR-122 expression are not effectively reduced
Solution Approach 1:
The patent extracts and targets the specific harmful factor miR-122 using complementary oligomers. The oligomers are designed with sequences specifically complementary to miR-122, allowing selective binding and inhibition of this particular microRNA that drives endothelial dysfunction and cardiovascular disease in diabetic patients.
Solution Approach 2:
The patent employs γ-diethylene glycol modifications to alter the physical and chemical parameters of the oligomer backbone. This γ-modification improves renal clearance, enhances solubility, and optimizes pharmacokinetic properties, enabling the oligomer to effectively reach and inhibit miR-122 while being safely eliminated from the body.
2Productivity
If γ-PNA oligomers with γ-diethylene glycol modification are used, then renal clearance and solubility are improved, but molecular structure complexity increases
Solution Approach 1:
The γ-diethylene glycol modification changes the physical parameters of the oligomer backbone, introducing flexibility and improving solubility while the repeating glycol units facilitate renal filtration. This parameter change optimizes both pharmacokinetic clearance and molecular behavior without requiring complex structural designs.
Solution Approach 2:
The γ-modification is applied locally at specific positions along the oligomer backbone rather than throughout the entire structure. This localized modification at the γ-position of nucleotide residues provides the desired renal clearance and solubility benefits while maintaining the overall simplicity and sequence-specific binding capability of the oligomer.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The γ-PNA oligomers effectively reduce miR-122 levels, improving endothelial function, lowering cardiovascular risk, and alleviating symptoms of hypertension and diabetes, as demonstrated by improved vascular function and histological outcomes.
Implementation Method 1
the oligomer comprising a nucleic acid sequence complementary to miR-122
Data Source
AI summary
Disclosed are compounds and methods for the treatment of diseases or disorders associated with expression of miR-122. More specifically, γ peptide nucleic acid (γPNA) inhibitors of miR-122 and methods of using the same are disclosed.